These protective immune cells are depleted in inflammatory bowel disease (IBD), leaving patients vulnerable to disease progression and severe complications. The findings could lead to better clinical management and treatment options for people living with these conditions.
IBD is the collective term for Crohn’s disease and ulcerative colitis, two currently incurable conditions which involve excessive inflammation in the gut, causing debilitating symptoms like pain and diarrhoea. IBD is common, affecting 1 in 125 people in the UK, and its incidence is growing globally. Often starting in childhood and early adult life, it impacts some of the most socially and economically important periods of a person’s life.
As part of their study, published today in Science, the researchers investigated tissue from over 150 patients at Guy’s and St Thomas’ NHS Foundation Trust, dissecting a major population of T cells called gamma delta (γδ) T cells in the colons of people with healthy guts and people with IBD. In healthy guts, there was a unique specialised subset of gamma delta cells, termed V-gamma-4 (Vg4) cells, that intriguingly were significantly altered and often conspicuously depleted in inflamed IBD samples.
Prior to this work, the team at the Crick and King’s had identified molecules in the healthy gut epithelium (the cells lining the gut walls) which directly interact with Vg4 T cells. So, in this new study they tested whether losing this normal interaction between Vg4 T cells and the epithelium was underpinning disease.
To do this, the team looked at relatively rare individuals carrying a gene that severely limits this interaction, and found that whereas carrying this gene didn’t increase the chance of developing IBD, for those who already developed Crohn’s Disease, it significantly increased the risk of disease progression and the development of severe complications.
The researchers also observed that, in people whose inflammation had improved, those with restored Vg4 T cell function were less likely to relapse than those who did not. This suggests that assessing the status of Vg4 T cells could be a useful biomarker for disease progression.
Robin Dart, former Wellcome trust funded PhD student at the Crick, postdoctoral clinical research fellow at King’s College London, and consultant gastroenterologist at Guy’s and St Thomas’ NHS Foundation Trust, said: “There’s currently no cure for IBD, and for a significant proportion of the patients I treat, persistent relapses are distressing, severely impacting their day-to-day lives. Treatments tend to focus on reducing inflammation, but despite improvements in therapy, relapse rates remain high. So, we need to start targeting other areas, such as repairing the gut barrier, and γδ T cells, particularly Vg4 cells, may offer a way to do this.”
People living with IBD are at an increased risk of developing colorectal cancer, especially when the disease is uncontrolled. In some cases, people develop cancerous or pre-cancerous gut lesions that need surgical removal.
Adrian Hayday, principal group leader of the Immunosurveillance Laboratory at the Crick, Kay Glendinning Professor of Immunobiology at King’s College London, and leader of the study, said: “The links between uncontrolled IBD and particularly severe forms of colon cancer aren’t well understood. So, it’s fascinating that the key immune cell subset that we have identified as missing in IBD, may also be the same as the gut γδ T cells described by another group in Milan as having profound potential to attack colon cancer cells. We think that defects in these cells could conceivably link the two diseases.
“I see gut γδ T cells as a vacuum cleaner clearing up damage done by infections and toxins coming in through a door which has to be kept open in order for food to pass through. If the γδ T cells aren’t working properly, damage accumulates, driving inflammation and potentially cancerous changes that can build to unchecked levels.”
The next steps for the research are to investigate potential drug targets for the interactions between γδ T cell and the epithelial cells and to refine approaches for routinely monitoring gut γδ T cells as a much-needed marker for IBD progression versus recovery. The broader implications of this immune cell biology on different body surfaces should also be a focus.
This research took place with thanks to all consenting patients and to the NIHR BioResource for support in providing additional samples.
For further information, contact: email@example.com or +44 (0)20 3796 5252
Notes to Editors
Reference: Dart, R. and Zlatareva I., et al. (2023). Conserved γδ T cell selection by BTNL proteins limits progression of human inflammatory bowel disease. Science. 10.1126/science.adh0301.
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.
The Crick was formed in 2015, and in 2016 it moved into a brand new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under a single roof in Europe.
About King’s College London
King’s College London is amongst the top 35 universities in the world and top 10 in Europe (THE World University Rankings 2023), and one of England’s oldest and most prestigious universities.
With an outstanding reputation for world-class teaching and cutting-edge research, King’s maintained its sixth position for ‘research power’ in the UK (2021 Research Excellence Framework).
King's has more than 33,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff.
Since its foundation, King’s students and staff have dedicated themselves in the service of society. King’s continues to focus on world-leading education, research and service, and will have an increasingly proactive role to play in a more interconnected, complex world. Visit the website to find out more about Vision 2029, King's strategic vision to take the university to the 200th anniversary of its founding.
World-changing ideas. Life-changing impact: kcl.ac.uk/news/headlines
About Guy’s and St Thomas’ NHS Foundation Trust
Contact: Guy’s and St Thomas’ NHS Foundation Trust tel: 020 7188 5577 or e-mail: firstname.lastname@example.org. Out of hours, please call our pager bureau on 0844 822 2888, ask for pager number 847704 and give the pager operator your message.
Guy's and St Thomas' provides 2.6 million patient contacts in acute and specialist hospital services and community services every year. The Trust includes Guy’s Hospital, St Thomas’ Hospital, Evelina London Children’s Hospital, Royal Brompton Hospital, Harefield Hospital, and adult and children’s community services in Lambeth and Southwark.
As one of the biggest NHS trusts in the UK, with an annual turnover of £2.8 billion, we employ around 25,300 staff. www.guysandstthomas.nhs.uk
Guy’s and St Thomas’ is part of King’s Health Partners Academic Health Sciences Centre (AHSC), a collaboration between King’s College London, and Guy’s and St Thomas’, King’s College Hospital and South London and Maudsley NHS Foundation Trusts. www.kingshealthpartners.org